2.77 USD
▲+0.07+4.53%
盘后 2.64 -0.38%
2026-08-03
市值
$425.09M
市盈率
—
EPS
-1.18
股息率
—
52 周区间
1.66 – 4.54
成交量
1.56M
Beta
2.06
目标价
5.78
52W 低 1.6652W 高 4.54
价格走势
公司简介
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated ...